The Therapeutic Catalyst accelerates the translation of laboratory discoveries into novel cancer therapeutics.
About
The Therapeutic Catalyst supports exploratory drug discovery efforts to validate and de-risk targets and technologies and position them for onward investment and progression. This provides you with the opportunity to take your research idea from bench to patients with a single funder and partner.
Funded projects run collaboratively between academic and Cancer Research Horizons drug discovery laboratories (Therapeutic Innovation), with joint decision-making and accountability for project progression.
At the proposal stage, you will be assigned a scientist from Therapeutic Innovation to support you throughout your project, working with you to build and pitch the proposal. These scientists bring significant expertise and serve as a single point of contact to manage all the internal (Cancer Research Horizons drug discovery) and external resources required to deliver your project.
We can also offer additional expertise, resources, and capabilities from across Cancer Research Horizons, Cancer Research UK, and our wider investigator network to help your project progress more effectively. Additionally, if appropriate, Cancer Research Horizons can support you in identifying and engaging with potential commercial partners or other options to accelerate the project toward patient benefit.
Scientific remit
This scheme aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering. We are seeking projects with strong therapeutic potential to deliver patient benefit.
We invite applications for early drug discovery proposals from across all cancer indications and modalities. Some examples of projects we might fund include the following areas:
This scheme is open to global applications.
Sponsor Institute/Organizations: Cancer Research UK
Sponsor Type:
Address: 2 Redman Place, London, E20 1JQ
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Oct 25, 2024
Oct 25, 2024
$250,000
5 awards available. Successful projects will receive up to £250k for up to 18 months.This funding covers resources externally from the applying academic laboratory and/or outsourced activities. Academic funding can be provided for staff time (research or technical) and any associated running expenses
Affiliation: Cancer Research UK
Address: 2 Redman Place, London, E20 1JQ
Website URL: https://www.cancerresearchuk.org/funding-for-researchers/our-funding-schemes/therapeutic-catalyst
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.